Kallikrein
KLK; Kallikrein-related peptidase
Kallikrein is a serine protease that plays a crucial role in the kallikrein-kinin system. Plasma kallikrein, specifically expressed in hepatocytes, acts on high molecular weight kininogen to release bradykinin, which is involved in regulating vascular tone, inflammatory response, and endogenous blood coagulation and fibrinolysis. Tissue kallikrein, widely distributed in various tissues such as the lung, kidney, and brain, acts on low molecular weight kininogen to produce kinin, participating in processes like blood pressure regulation, electrolyte balance, and neuronal protection. Additionally, kallikrein can bind to LDLR, promoting its lysosomal degradation, and interact with ASICs to affect neuronal function in the central nervous system. Dysregulation of kallikrein activity is associated with various diseases including heart disease, kidney disease, and cancer[1][2].
References:
- [1]. Raspi G. Kallikrein and kallikrein-like proteinases: purification and determination by chromatographic and electrophoretic methods. J Chromatogr B Biomed Appl. 1996 Sep 20;684(1-2):265-87. [Content Brief]
- [2]. Yousef GM, et al. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev. 2001 Apr;22(2):184-204. [Content Brief]
Kallikrein Isoform Specific Products
All Product Categories
-
Kallikrein Related Products (64)
Related Products (64)
-
Antibodies (4)
-
Kallikrein Isoform Comparison
-
Feniralstat hydrochloride
0 ImagesCat. No.: HY-145568ACAS No.: 2340299-00-3Feniralstat (compound 30) hydrochloride, a pyrazole derivative, is a potent kallikrein inhibitor with an IC50 of 6.7 nM for Human plasma kallikrein (pKal). Feniralstat has no inhibition on Human KLKl, Human FXIa, Human Factor Xlla (all IC50>40 μM).
-
Onvuzosiran
0 ImagesCat. No.: HY-177652CAS No.: 2982817-49-0Onvuzosiran, a siRNA, is a prekallikrein synthesis reducer.
-
Berotralstat-d4-1
0 ImagesCat. No.: HY-109127SSynonyms: BCX7353-d4-1Berotralstat-d4-1 (BCX7353-d4-1) is the deuterium labeled Berotralstat (HY-109127). Berotralstat (BCX7353) is an orally active plasma kallikrein inhibitor. Berotralstat can reduce brain edema and is being studied for glioblastoma and hereditary angioedema.
-
FXIa/Plasma kallikrein-IN-1
0 ImagesCat. No.: HY-150519CAS No.: 1551460-43-5FXIa/Plasma kallikrein-IN-1 is an inhibitor of coagulation factor XIa (FXIa) and plasma kallikrein with Ki values of 187.70 nM and 151.6 nM, respectively. FXIa/Plasma kallikrein-IN-1 can be used in the research of thromboembolic diseases.
-
Cy3 labled Donidalorsen sodium
0 ImagesCat. No.: HY-139787E
-
Onvuzosiran sodium scrambled negative control
0 ImagesCat. No.: HY-177652BOnvuzosiran sodium scrambled negative control is the sequence scrambled negative control of Onvuzosiran sodium.
-
Plasma kallikrein-IN-2
0 ImagesCat. No.: HY-143476Plasma kallikrein-IN-2 (Compound 198) is a potent plasma kallikrein (PKal) inhibitor with an IC50 of 0.1 nM. Plasma kallikrein-IN-2 can be used for hereditary angioedema, diabetic macular edema, and diabetic retinopathy research.
-
Plasma kallikrein-IN-3
0 ImagesCat. No.: HY-150052CAS No.: 1357950-47-0Plasma kallikrein-IN-3 is a plasma kallikrein inhibitor (IC50: 0.15 μM). Plasma kallikrein-IN-3 can be used for hereditary angioedema, diabetic macular edema, and diabetic retinopathy research.
-
DPC423 free base
0 ImagesCat. No.: HY-11090CAS No.: 209957-47-1DPC423 free base is a selective and orally active factor Xa inhibitor with a Kis of 0.15 (human) and 0.3 (rabbit) nM. DPC423 free base exhibits Kis of 60, 61 and 6000 nM against human trypsin, plasma kallikrein and thrombin. DPC423 free base blocks the formation of prothrombinase complex, reduces thrombin production, inhibits fibrin formation and platelet activation. DPC423 free base can be used for the study of anticoagulation of arterial thrombosis.
-
FAM labled Donidalorsen sodium
0 ImagesCat. No.: HY-139787D
-
DKFZ-938
0 ImagesCat. No.: HY-189205DKFZ-938 is a kallikrein-related peptidase 6 (KLK6) inhibitor, with an IC50 of 0.09 μM against human KLK6. DKFZ-938 binds to the catalytic serine residue in the active-site pocket of KLK6 and mimics the natural KLK6 substrate to inhibit the enzymatic activity of KLK6. DKFZ-938 can be conjugated to the non-canonical amino acid propargyllysine via copper-catalyzed azide-alkyne cycloaddition click chemistry. DKFZ-938 is used in research related to colorectal cancer and pancreatic cancer.
-
Ono 3307 free base
0 ImagesCat. No.: HY-167924CAS No.: 76472-28-1Ono 3307 Free base is a novel synthetic protease inhibitor that exhibits protective effects against acute pancreatitis by preventing hyperamylasemia and pancreatic edema. Ono 3307 Free base also inhibits the redistribution of lysosomal enzymes in acinar cells and mitigates lactic dehydrogenase discharge. Ono 3307 Free base effectively reduces cathepsin B leakage from lysosomes in a dose-dependent manner. Ono 3307 Free base is able to target trypsin (Ki=48 nM), thrombin (Ki=0.18 μM), plasma kallikrein (Ki=0.29 μM), plasmin (Ki=0.31 μM), pancreatic kallikrein (Ki=3.6 μM), and chymotrypsin (Ki=47 μM).
-
KLK6-IN-1
0 ImagesCat. No.: HY-182600CAS No.: 2370980-52-0KLK6-IN-1 is a reversible small‑molecule inhibitor of KLK6, KLK1, and plasmin. KLK6-IN-1 shows IC50 values of 1.57 μM (KLK6), 5.1 μM (KLK1), 7.4 μM (plasmin), and Ki values of 0.8 μM (KLK6), 2.4 μM (KLK1), 1.3 μM (plasmin). KLK6-IN-1 is highly selective for KLK6 and its proteolytic network. KLK6-IN-1 induces oligodendrocyte differentiation by promoting oligodendrocyte precursor cell maturation. KLK6-IN-1 can be used for the research of multiple sclerosis.
-
ONO-3307
0 ImagesCat. No.: HY-19101CAS No.: 76472-29-2ONO-3307 is a protease inhibitor that competitively inhibits a variety of proteases including trypsin, thrombin, plasma kallikrein, plasmin, pancreatic kallikrein, and chymotrypsin. ONO-3307 alleviates endotoxin-induced experimental disseminated intravascular coagulation (DIC) in rats. ONO-3307 can be used in the study of thrombosis and protease-mediated diseases.
-
Picrasidine J
0 ImagesCat. No.: HY-N16719CAS No.: 100234-62-6Picrasidine J is a selective inhibitor targeting the KLK-10 protease and the ERK signaling pathway. Picrasidine J inhibits epithelial-mesenchymal transition (EMT) by upregulating E-Cadherin and ZO-1 and downregulating β-catenin and Snail, while simultaneously reducing KLK-10 expression and inhibiting ERK phosphorylation, thereby exhibiting significant anti-migratory and anti-invasive activity. Picrasidine J can inhibit the metastasis of head and neck squamous cell carcinoma (HNSCC) and is primarily used in anti-metastasis research for head and neck tumors.
-
Donidalorsen
0 ImagesSynonyms: ISIS-721744 free acid; IONIS-PKK-LRX free acidDonidalorsen (ISIS-721744; IONIS-PKK-LRX free acid) is an antisense oligonucleotide targeting prekallikrein (PKK). Donidalorsen inhibits kallikrein activity and reduces the production of Bradykinin (HY-P0206) by specifically binding to and degrading PKK mRNA in the liver. Donidalorsen can be used in the research of hereditary angioedema.
-
Bz-Pro-Phe-Arg-pNA
0 ImagesCat. No.: HY-126809CAS No.: 58840-30-5Synonyms: Bz-PFR-pNABz-Pro-Phe-Arg-pNA (Bz-PFR-pNA) is a chromogenic peptide substrate for plasma and glandular Kallikrein, cysteine proteinase (Cruzipain) and Trypsin. Bz-Pro-Phe-Arg-pNA can be used in Factor XII assay.
-
Cbz-Lys-Arg-pNA
0 ImagesCat. No.: HY-P5027CAS No.: 108318-37-2Cbz-Lys-Arg-pNA is a peptide substrate containing pNA as the chromogenic group. Cbz-Lys-Arg-pNA is widely used in enzymatic analysis, including thrombin, plasmin, factor Xa and Kallikrein.
-
KLK5/14-IN-1
0 ImagesCat. No.: HY-100497CAS No.: 1087624-28-9KLK5/14-IN-1 is a selective human skin kallikrein inhibitor with IC50 values of 0.048 μM, 0.2 μM, and 0.1 μM for KLK7, KLK5, and KLK14, respectively. KLK5/14-IN-1 shows no or only low inhibitory activity against Cathepsin G, Chymotrypsin, Trypsin, and Thrombin. KLK5/14-IN-1 can be used in research related to Netherton syndrome.
